3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
DMK Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2022 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for DMK Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
DMKPQ's 3-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.72 * Ranked among companies with meaningful 3-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
DMK Pharmaceuticals 3-Year ROIIC % Related Terms
DMK Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for DMK Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMKPQ vs CNNC, THCT, VFRM: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's 3-Year ROIIC % falls into.
DMK Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -25.059 (Dec. 2022) - -29.029 (Dec. 2019) )
/
( 3.607 (Dec. 2022) - 36.678 (Dec. 2019) )
=
3.97
/
-33.071
=
-12.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
DMK Pharmaceuticals (DMKPQ) has a 3-Year ROIIC % of 0.00 as of Dec. 2022. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' 3-Year ROIIC % too high?
DMK Pharmaceuticals' current 3-Year ROIIC % is 0.00. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' 3-Year ROIIC % compare to CNNC and THCT?
DMK Pharmaceuticals' 3-Year ROIIC % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year ROIIC % is 3.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on DMK Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DMK Pharmaceuticals's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current 3-Year ROIIC % is 0.00 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score
Get the complete analysis for DMKPQ
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMKPQ has been successfully added to your 
